Enzymatica AB: Bulletin from annual general meeting 2017 in Enzymatica AB (publ)
(Thomson Reuters ONE) -
Press Release
Lund April 20, 2017
Bulletin from annual general meeting 2017 in Enzymatica AB (publ)
Enzymatica held its annual general meeting today 20 April 2017 in Lund. The
annual general meeting resolved upon the following:
Appropriation of profit/loss
The annual general meeting resolved to adopt the income statements and the
balance sheets of the group and parent company and resolved to carry forward the
funds available at the annual general meeting and, consequently, resolved not to
distribute any dividend for the financial year 2016.
Discharge from liability for the members of the board of directors and the CEO
The annual general meeting discharged the board of directors and the CEO from
liability for the financial year 2016.
Board of directors and auditor
The annual general meeting resolved to re-elect Bengt Baron, Mats K Andersson,
Guðmundur Pálmason, Marianne Dicander Alexandersson, Sigurgeir Guðlaugsson and
Louise Nicolin as members of the board of directors. Bengt Baron was re-elected
chairman of the board.
The annual general meeting resolved to appoint Deloitte AB as new auditor of the
company for the period until the end of the next annual general meeting.
Deloitte AB has informed that Per-Arne Pettersson will be auditor in charge.
Remuneration to the board of directors and the auditor
The annual general meeting resolved that the total fees to the board of
directors will amount to SEK 950,000, excluding remuneration for committee work,
of which SEK 350,000 will be paid to the chairman and SEK 120,000 to each of the
other members elected at the annual general meeting and not employed by the
company. SEK 50,000 will be paid for work performed by the chairman of the audit
committee and no remuneration will be paid to the other members. No remuneration
will be paid to the members of the remuneration committee.
The annual general meeting resolved that fees to the auditor shall be paid
according to approved invoice.
Guidelines for remuneration for senior executives
The annual general meeting resolved in accordance with the board of directors'
proposal on guidelines for remuneration for senior executives.
Authorization of the board to issue new shares
The annual general meeting resolved to authorize the board to issue a maximum of
9,000,000 shares with or without deviation from the shareholders' preferential
rights, to raise new capital and to take advantage of future opportunities to
attract new long-term owners of strategic importance to the company, as well as
to finance the company's growth strategy.
Resolution on personnel option program
The annual general meeting resolved in accordance with the proposal for
resolution to adopt a personnel option program and resolution to issue directed
warrants as well as approval of transfer of warrants. The program entails that a
maximum of 3,750,000 personnel options shall be offered to a by the board
elected circle of individuals from and including 21 April 2017 to and including
1 May 2017. The holders can utilize the allotted personnel options until 31 July
2023. Each personnel option confers a right to acquire one new share in the
company against cash consideration at a utilization price of 150% of the average
value of the Enzymatica share on Nasdaq First North during the period from and
including 5 April 2017 to and including 19 April 2017. The personnel options
shall be allotted without consideration and shall not constitute securities and
shall not be able to be transferred or pledged.
In order to enable the delivery of shares as well as to hedge ancillary costs,
primarily social security charges, a maximum of 4,928,250 warrants shall be
issued to the wholly owned subsidiary of Enzymatica Care AB which thereafter may
be transferred to the participants without consideration in connection with the
utilization of personnel options. The maximum dilution effect of the program is
approximately 5.1 percent.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg(at)enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device
products against infectious-related diseases. Over a short period the company
has developed a unique oral spray for colds, ColdZyme®, and launched it on eight
markets. The product has become one of the leading articles for colds in Swedish
pharmacies. Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical markets through
well-established partners. The company is headquartered in Lund, Sweden and is
listed on Nasdaq First North. For more information, please visit
www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser Bank.
Enzymatica Bullentin from AGM April 20, 2017:
http://hugin.info/160850/R/2097279/793787.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2017 - 16:38 Uhr
Sprache: Deutsch
News-ID 537457
Anzahl Zeichen: 5868
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Enzymatica AB: Bulletin from annual general meeting 2017 in Enzymatica AB (publ)"
steht unter der journalistisch-redaktionellen Verantwortung von
Enzymatica AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
